卵巢上皮性癌组织中激肽释放酶7及14的表达及临床意义

Expressions of kallikrein 7 and 14 in human epithelial ovarian cancer and its clinical significance

目的研究激肽释放酶(kallikrein,KLK)7及KLK14在卵巢上皮性癌组织中的表达,并探讨其临床意义。方法采用RT-PCR及Western-blot技术测定KLK7及KLK14在50例不同临床分期、不同组织分级的卵巢上皮性癌中mRNA及蛋白表达。结果KLK7在卵巢癌中表达明显增高,且低分化组织较高分化组织表达高(P<0.01);KLK14在卵巢癌中表达亦增高(P<0.05),且晚期卵巢癌(Ⅲ、Ⅳ期)明显高于早期卵巢癌(Ⅰ、Ⅱ期,P<0.01);G3级卵巢癌高于G1、G2级卵巢癌(P<0.05)。结论KLK7、KLK14在卵巢癌的发生及转移中有潜在促进作用。

Objective To evaluate the expressions of kallikrein 7（KLK7） and 14（KLK14） in human epithelial ovarian cancers and to discuss its clinical significance in malignant tumors. Methods RT-PCR and Western-blot were used to determine the expressions of KLK7 and KLK14 mRNA and proteins in 50 epithelial ovarian cancers with different clinical stages and different histologieal grades. Results The expressions of KLK7 mRNA and protein in ovarian cancers were significantly higher than those in benign tumors（ P 〈 0.01） and were markedly associated with the histological differentiation （ P 〈 0.01 ）, also the expressions of KLK14 mRNA and protein in ovarian cancers were higher than those in benign tumors（P 〈 0.05）and were associated with the histological differentiation（ P 〈 0.05）, and the expression of KLK14 in advanced stages （ Ⅲ and Ⅳ stage） was higher than that in early stages （Ⅰ and Ⅱ stage, P〈 0.01）. Conclusion KLK7 and KLK14 play potential roles in the pathogenesis and metastasis of ovarian cancer.